A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

NCT04197817 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: JS002
DRUG: Placebo

Sponsor

Shanghai Junshi Bioscience Co., Ltd.